Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 21, which means every article in Clinical Investigation has got 21 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

  2020 2019 2018 2017 2016

Year wise published articles

28 19 22 19 2

Year wise citations received

222 233 233 230 181
Journal total citations count 1936
Journal impact factor 6.44
Journal 5 years impact factor 12.56
Journal cite score 10.78
Journal h-index 21
Journal h-index since 2016 18
Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/
{Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3
  • Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A, Taha MK, Toropainen M, Tzanakaki G. Meningococcal serogroup Y emergence in Europe: update 2011. Human vaccines & immunotherapeutics. 2012 Dec 1;8(12):1907-11. View at Publisher | View at Google Scholar | View at Indexing
  • Hellenbrand W, Koch J, Harder T, Bogdan C, Heininger U, et al. (2015) Tenenbaum T, Terhardt M, Vogel U, Wichmann O, von Kries R. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 58: 1314-1343. View at Publisher | View at Google Scholar | View at Indexing
  • Zwiauer KF, Bröker M, Banzhoff A (2014) Der neue Mehrfachkomponentenimpfstoff 4CMenB zum Schutz vor Erkrankungen durch Meningokokken der Serogruppe B. Pädiatrie & Pädologie 49: 3-12. View at Publisher | View at Google Scholar | View at Indexing
  • Keogh J, Krägeloh CU, Shepherd D, Ryan C, Osborne S, et al. (2013) Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy. Journal of Cancer Research and Therapy 1: 105-110.

    View at Publisher | View at Google Scholar
  • Li X, Xue H, Kang Q, Sun H, Yang S, et al. (2014) Alterations of the interstitial cells of Cajal and the microstructure of the gastrointestinal tract in KIT distal kinase mutant mice. Cell and tissue research 355: 49-58. View at Publisher | View at Google Scholar | View at Indexing
  • Scherer DG, Brody JL, Annett RD, Turner C, Dalen J, et al. (2013) Empirically derived knowledge on adolescent assent to pediatric biomedical research. AJOB primary research 4: 15-26. View at Publisher | View at Google Scholar | View at Indexing
  • Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, et al. (2014) Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PloS one 9: e110216. View at Publisher | View at Google Scholar | View at Indexing
  • Licitra L, Mesía R, Keilholz U (2016) Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. Oral oncology 52: 18-23. View at Publisher | View at Google Scholar | View at Indexing
  • Hahn EA, Kallen MA, Jensen RE, Potosky AL, Moinpour CM, et al. (2016) Measuring Social Function in Diverse Cancer Populations: Evaluation of Measurement Equivalence of the Patient Reported Outcomes Measurement Information System®(PROMIS®) Ability to Participate in Social Roles and Activities Short Form. Psychological Test and Assessment Modeling 58: 403. View at Publisher | View at Google Scholar | View at Indexing
  • Cella D, Teresi JA. Elizabeth A. Hahn1, Michael A. Kallen2, Roxanne E. Jensen3, Arnold L. Potosky3, Carol M. Moinpour4, Mildred Ramirez5. View at Publisher | View at Google Scholar | View at Indexing
  • Hepgur M, Sadeghi S, Dorff TB, Quinn DI (2013)Tivozanib in the treatment of renal cell carcinoma. Biologics 7: 139-148. View at Publisher | View at Google Scholar | View at Indexing
  • Hampson LV, Whitehead J, Eleftheriou D, Brogan P (2014) Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Statistics in medicine 33: 4186-4201. View at Publisher | View at Google Scholar | View at Indexing
  • Billingham L, Malottki K, Steven N (2016) Research methods to change clinical practice for patients with rare cancers. The Lancet Oncology 17: e70-e80. View at Publisher | View at Google Scholar | View at Indexing
  • Hampson LV, Herold R, Posch M, Saperia J, Whitehead A (2014) Bridging the gap: a review of dose investigations in paediatric investigation plans. British journal of clinical pharmacology 78: 898-907. View at Publisher | View at Google Scholar | View at Indexing
  • Hincapié CA, Cassidy JD, Rampersaud R, Pierre Côté DC, Jadad AR, Tomlinson GA. Chiropractic Spinal Manipulation Treatment and the Risk For 3 Acute Lumbar Disc Herniation: A Belief Elicitation Study. Chiropractic Care and Risk For Acute Lumbar Disc Herniation: A Mixed Methods Approach. 2015:65. View at Publisher | View at Google Scholar | View at Indexing
  • i Alapont VM, Khemani RG, Medina A, del Villar Guerra P, Cambra AM. Bayes to the Rescue: Continuous Positive Airway Pressure Has Less Mortality Than High-Flow Oxygen. Pediatric Critical Care Medicine. 2017 Feb 1;18(2):e92-9. View at Publisher | View at Google Scholar | View at Indexing
  • Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice?. Clinical Trials. 2016 Oct 10:1740774516673362.

    View at Publisher | View at Google Scholar
  • Lewiecki EM (2011) Welcome to Clinical Investigation. Clinical Investigation (1):1-2. View at Publisher | View at Google Scholar | View at Indexing
  • Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience 14: 401-416. View at Publisher | View at Google Scholar | View at Indexing
  • Lu B, Nagappan G, Nathan PJ, Blin O (2013) Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. Drug Discovery Today: Therapeutic Strategies 10: e99-e104. View at Publisher | View at Google Scholar | View at Indexing
  • (2011) Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Diseases May 1;52(suppl 5):S397-428.

    View at Publisher | View at Google Scholar
  • Young JS, Simmons JW (2014) Chemotherapeutic medications and their emergent complications. Emergency medicine clinics of North America 32: 563-578. View at Publisher | View at Google Scholar | View at Indexing
  • (2012) Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clinical Infectious Diseases. Aug 13:cis688. View at Publisher | View at Google Scholar | View at Indexing
  • Spellberg B, Bartlett J, Wunderink R, Gilbert DN (2015) Novel approaches are needed to develop tomorrow’s antibacterial therapies. American journal of respiratory and critical care medicine191(2):135-40. View at Publisher | View at Google Scholar | View at Indexing
  • Spellberg B (2014) The future of antibiotics. Critical care 18(3):228. View at Publisher | View at Google Scholar | View at Indexing
  • Favaloro EJ, Plebani M, Lippi G (2013) Regulation in hemostasis and thrombosis: part I—in vitro diagnostics. InSeminars in thrombosis and hemostasis 39: 235-249.

    View at Publisher | View at Google Scholar
  • Shlaes DM, Spellberg B (2012) Overcoming the challenges to developing new antibiotics. Current opinion in pharmacology 12(5):522-6. View at Publisher | View at Google Scholar | View at Indexing
  • Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. InSeminars in thrombosis and hemostasis 2014 Jul (Vol. 40, No. 05, pp. 551-570). Thieme Medical Publishers.

    View at Publisher | View at Google Scholar
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, et al. (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation : CIR-0000000000000031.

    View at Publisher | View at Google Scholar
  • Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, et al. (2006) ACC/AHA 2006 practice guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of .... Journal of the American College of Cardiology 48: 598-675. View at Publisher | View at Google Scholar | View at Indexing
  • Guyton RA, Sundt III TM, Albert NM, Hochman FJ, Bozkurt FB, et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Circulation129:000-. View at Publisher | View at Google Scholar | View at Indexing
  • Albert NM, Bozkurt B, Curtis LH, DeMets D, Guyton RA, et al. (2014) AHA/ACC Guideline. Circulation 129: e521-e643. View at Publisher | View at Google Scholar | View at Indexing
  • Nishimura, Rick A., et al. "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines." Journal of the American College of Cardiology 63.22 (2014): e57-e185. View at Publisher | View at Google Scholar | View at Indexing
  • Hennekens CH, Borzak S, Bjorkman DJ. Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making. View at Publisher | View at Google Scholar | View at Indexing
  • Fleming TR, Hennekens CH, Pfeffer MA, DeMets DL (2014) Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. Journal of biopharmaceutical statistics 24(5):968-75. View at Publisher | View at Google Scholar | View at Indexing
  • Garber AJ, Newcomer JW, Hennekens CH (2013) Lower A1c targets in type 2 diabetes and increased mortality: causal or casual?. The American journal of medicine 126(12):1033-4. View at Publisher | View at Google Scholar | View at Indexing
  • Wittes J (2016) Independent Data Monitoring Committees in Multiregional Clinical Trials. InMultiregional Clinical Trials for Simultaneous Global New Drug Development (pp. 151-166). View at Publisher | View at Google Scholar | View at Indexing
  • Mason PH, Degeling C (2016) Beyond biomedicine: Relationships and care in tuberculosis prevention. Journal of bioethical inquiry. 13: 31-34.

    View at Publisher | View at Google Scholar
  • Lewiecki EM (2011) Welcome to Clinical Investigation. Clinical Investigation (1):1-2.

    View at Publisher | View at Google Scholar
  • Qi H, Chen L, Liu B, Wang X, Long L, et al. (2014) Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents. Bioorganic & medicinal chemistry letters 24(4):1108-10.

    View at Publisher | View at Google Scholar
  • Arreola A, Rathmell WK (2013) Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects). InRenal Cell Carcinoma (pp. 231-247) View at Publisher | View at Google Scholar | View at Indexing
  • Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G (2012) HER2 status in unusual histological variants of gastric adenocarcinomas. Journal of clinical pathology 65(3):237-41. View at Publisher | View at Google Scholar | View at Indexing
  • Park SR, Park YS, Ryu MH, Ryoo BY, Woo CG et al. (2016) Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer 53:42-50. View at Publisher | View at Google Scholar | View at Indexing
  • Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB (2012) Denosumab for the Prevention of Skeletal‐Related Events in Patients with Bone Metastasis from Solid Tumor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32(3):274-84. View at Publisher | View at Google Scholar | View at Indexing
  • Salesi M, Mottaghi P, Karimifar M, Farajzadegan Z (2012) Intravenous pamidronate for refractory rheumatoid arthritis. Journal of Research in Medical Sciences 17(5). View at Publisher | View at Google Scholar | View at Indexing
  • 李红星, 柳立军, 景原雪, 刘梦伊, 薛石龙. 促性腺激素释放激素拮抗剂在性激素依赖性疾病中的应用. 中国新药杂志. 2012;21(20):2394-7. View at Publisher | View at Google Scholar | View at Indexing
  • Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J (2013) Targeting signaling pathways in epithelial ovarian cancer. International journal of molecular sciences 14: 9536-9555.

    View at Publisher | View at Google Scholar
  • Garces ÁH, Dias MS, Paulino E, Ferreira CG, de Melo AC (2015) Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?. Cancer chemotherapy and pharmacology. 75: 221-234.

    View at Publisher | View at Google Scholar
  • Choonara I (2014) Paediatric research environment in the UK. Paediatrics and Child Health 24: 370-373.

    View at Publisher | View at Google Scholar
  • Laufs U (2014) Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. European heart journal Jun 10:ehu228. View at Publisher | View at Google Scholar | View at Indexing

Relevant Topics